STAMFORD, Conn., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on
developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral
kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the Stifel
2016 Healthcare Conference on Tuesday, November 15, 2016, at 1:30 p.m. ET in New York City.
A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the
Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website
for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new
chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is
developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have
demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects
typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Steve Silver Stern Investor Relations, Inc. 212-362-1200 Steve@sternir.com MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 astarr@6degreespr.com
